Results
1 -
10 of
18Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes, Synthesis of Heterocycles in Contemporary Medicinal Chemistry The influence of mutations upon the synthesis of RNA polymerase subunits in Escherichia coli cells, Molecular and General Genetics MGG Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes, Clinical Pharmacokinetics Clinical implication of SGLT2 inhibitors in type 2 diabetes, Archives of Pharmacal Research Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease, Clinical Pharmacokinetics Luseogliflozin: First Global Approval, Drugs Luseogliflozin/tofogliflozin, Reactions Weekly Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study, Diabetes Therapy Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study, Advances in Therapy